[{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"$28.3 million","newsHeadline":"Lupin Acquires Brands ONDERO\u00ae and ONDERO MET\u00ae to Expand Diabetes Portfolio in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"USV Private Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Linagliptin
Liralin (linagliptin) is a DPP-4 (Dipeptidyl peptidase IV) inhibitor, oral small molecule drug which is approved for the treatment of type-2-diabetes mellitus.
Through the acquisition, Lupin expands its diabetes portfolio in India by gaining access to Ondero (linagliptin) and Ondero Met (linagliptin & metformin). Ondero is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes.